Rivista in lingua italiana
riservata ai Soci SISA
Ultimo numero:
Anno 13 • N.4/2022
Cardiovascular disease (CVD) prevention is defined as a coordinated set of actions, at the population level or targeted at an individual, that are aimed at eliminating or minimizing the impact of CVDs and their related disabilities.1 CVD remains a leading cause of morbidity and mortality, despite improvements in outcomes. Age-adjusted coronary artery disease (CAD) mortality has declined since the 1980s, particularly in high-income regions.2 CAD rates are now less than half what they were in the early 1980s in many countries in Europe, due to preventive measures including the success of smoking legislation. However, inequalities between countries persist and many risk factors, particularly obesity3 and diabetes mellitus (DM),4 have been increasing substantially. If prevention was practised as instructed it would markedly reduce the prevalence would markedly reduce the of CVD. It is thus not only prevailing risk factors that are of concern, but poor implementation of preventive measures as well.5, 6 Prevention should be delivered (i) at the general population level by promoting healthy lifestyle behaviour7 and (ii) at the individual level, i.e. in those subjects at moderate to high risk of CVD or patients with established CVD, by tackling unhealthy lifestyles (e.g. poor-quality diet, physical inactivity, smoking) and by optimising risk factors. Prevention is effective: the elimination of health risk behaviours would make it possible to prevent at least 80% of CVDs and even 40% of cancers.
Eur J Prev Cardiol. 2016;23:NP1-NP96
Napoli, 26-28 novembre 2023
Rimini,
16-18 aprile 2023
Castelbuono (PA),
14 Novembre 2022
Modena, 7-9 Luglio 2022
[continua a leggere]Rivista in lingua italiana
riservata ai Soci SISA
Ultimo numero:
Anno 13 • N.4/2022
Rivista Italiana della
Ipercolesterolemia
Familiare Omozigote
Anno 4 • N.1/2022
Nuovo sito dedicato al Progetto LIPIGEN
Progetto LIPIGEN - Vecchio portale
E' necessario essere loggati come utente
Lipigen per poter accedere alla pagina
PROSISA – PROject Statin Intolerance SISA
E' necessario essere loggati come utente
PROSISA per poter accedere alla pagina
Gruppo Interdisciplinare Lipoprotein Aferesi
(Accesso Gruppo GILA-Lipoprotein Aferesi)
E' necessario essere loggati come utente del Gruppo GILA per poter accedere
Gruppo Interdisciplinare Lipoprotein Aferesi
(Documentazione ad accesso libero)
Pagina informativa per medici e pazienti